Community Transmission of Severe Acute Respiratory Syndrome Coronavirus 2, Shenzhen, China, 2020

Jiaye Liu,¹ Xuejiao Liao,¹ Shen Qian, Jing Yuan, Fuxiang Wang, Yingxia Liu, Zhaoqin Wang, Fu-Sheng Wang, Lei Liu, Zheng Zhang

Since early January 2020, after the outbreak of coronavirus infection in Wuhan, China, ${\approx}365$ confirmed cases have been reported in Shenzhen, China. The mode of community and intrafamily transmission is threatening residents in Shenzhen. Strategies to strengthen prevention and interruption of these transmissions should be urgently addressed.

In December 2019, an outbreak of a novel coronavirus infection (COVID-19), occurred in Wuhan, China (1). Although China launched an emergency response early in the outbreak, the infection rapidly spread to metropolitan areas in China and around the world. The growing number of cases suggests that the epidemic has continued to spread. Several research articles have reported the epidemiologic characteristics of the outbreak in Wuhan and Hubei Province (1–4); however, to our knowledge, an analysis of the epidemic in metropolis areas around Wuhan has not yet been reported. To predict the epidemic trend and guide control measures, especially in similar metropolitan areas, outbreak investigations are needed.

Shenzhen, a modern and international metropolitan city, is located in southern China (Appendix Figure 1, https://wwwnc.cdc.gov/EID/article/26/6/20-0239-App1.pdf) and has a population of 13 million persons, among which >1 million are from Hubei Province and >70,000 from Wuhan. After the first cluster of COVID-19 cases was confirmed in Shenzhen in early January 2020 (W.J. Guan

Author affiliations: Shenzhen Third People's Hospital, Shenzhen, China (J. Liu, X. Liao, S. Qian, J. Yuan, F. Wang, Y. Liu, Z. Wang, L. Liu, Z. Zhang); Southern University of Science and Technology, Shenzhen (Y. Liu, L. Liu, Z. Zhang); The Fifth Medical Center of PLA General Hospital, Beijing, China (F.-S. Wang)

DOI: https://doi.org/10.3201/eid2606.200239

et al., unpub. data, https://doi.org/10.1101/2020.02 .06.20020974), other cases spread within the city, involving all districts. To summarize the epidemiologic characteristics and provide updated information to aid in the development of control measures, we analyzed data for the first 365 laboratory-confirmed cases of COVID-19 in Shenzhen.

The Cases

In early January 2020, a total of 24 days after the index COVID-19 case occurred in Wuhan, a familial cluster of COVID-19 case-patients who had traveled to Wuhan from December 29, 2019, through January 4, 2020, was identified in Shenzhen (5). Subsequently, more cases in the city were reported. Analysis of spatiotemporal dynamics indicated that the infection spread more broadly throughout the city (Figure; Appendix Figure 2). Since January 17, infections increased substantially, peaking January 22–30. The decline since January 30 is probably the result of underascertainment of cases with recent onset and delayed identification or reporting (Figure).

Evaluation of the potential risk for local transmission will help determine whether patients with newly reported cases had definite exposure, defined by either having had definite contact with confirmed casepatients or having traveled to Wuhan or other cities in Hubei, or both, over the past 14 days. Overall, most (91%) cases that we report had definite exposure. On January 14, the first infected case-patient without definite exposure was reported in Shenzhen. Since January 20, growing numbers of cases without definite exposure were observed. Compared with the proportion before January 24, the proportion of case-patients without definite exposure was much higher from

¹These authors contributed equally to this article.




Figure. Onset of illness timeline for the first 365 confirmed COVID-19 case-patients in Shenzhen, China. The decline in incidence after January 30, 2020, probably resulted from delays in diagnosis and laboratory confirmation. All cases in this curve were confirmed. Hospital-based surveillance began January 8, 2020, for patients with suspected cases, defined by having a history of travel to Wuhan within the past 14 days, fever, and radiographic evidence of viral pneumonitis. PCR confirmation began January 13, 2020, and subsequently expanded the criteria for patients with suspected cases, defined by having typical clinical manifestations of COVID-19 and excluding infection caused by type A and B influenza and respiratory syncytial virus, regardless of travel history. NCIP, novel coronavirus—infected pneumonia (now called COVID-19).

January 25 through February 5 (11% vs. 6%; p<0.001) and increased to 36% (12/33) on both January 31 and February 5. These data suggest an increasing risk for community transmission (Table 1; Figure).

We analyzed the clinical and epidemiologic characteristics of 365 persons with laboratory-confirmed

cases in Shenzhen. The median case-patient age was 46 (range 1–86) years; 182 (50%) case-patients were male. To investigate the shift of the epidemic, we compared characteristics of case-patients during 2 periods: before January 24 (the Chinese Spring Festival) and after January 25 (until February 5). Because of delays between

Table 1. Characteristics of patients with severe acute respiratory syndrome coronavirus 2 infection in Shenzhen, China, as of February 5, 2020

Characteristic	Before Jan 24, n = 166	Jan 25–Feb 5, n = 199	p value
Median age (range), y	52 (1–81)	40 (1–86)	<0.001
Age group, no. (%)			<0.001
<15	4 (2)	26 (13)	
15–34	30 (18)	44 (22)	
35–54	60 (36)	70 (35)	
<u>≥</u> 55	72 (43)	59 (30)	
Patient sex, no. (%)			0.428
M	79 (48)	103 (52)	
F	87 (52)	96 (48)	
Exposure history, no. (%)			<0.001
Contact with confirmed case-patients	71 (43)	109 (55)	
Wuhan	78 (47)	42 (21)	
Cities other than Wuhan in Hubei Province	7 (4)	26 (13)	
No definite exposure	10 (6)	22 (11)	
First visited designated hospital, no. (%)	22 (13)	29 (15)	0.717
Days between illness onset and visiting hospital, median (range)	3 (0–15)	1 (0-9)	<0.001

Table 2. Estimated incubation periods for severe acute respiratory syndrome coronavirus 2, stratified by exposure classification, Shenzhen, China, as of February 5, 2020

Exposure	No. patients	Mean, d	Median, d	Interquartile range, d	Range, d
Contact with confirmed symptomatic case-patient	33	6.1	5	3–8	1–16
Traveled to Wuhan and stayed ≤1 day	25	6.0	5	3–8	1–15
Total	58	6.0	5	3–8	1–16

infection to illness onset or illness onset to confirmation, the following comparisons between the 2 periods might be biased because of misclassification.

We found a sharply increasing proportion of infected children (from 2% before January 24 to 13% for January 25-February 5; p<0.001), implying that increased exposure for children and intrafamily transmission might contribute substantially to the epidemic. Although substantially higher after January 25, 2020, the proportion of infected children in our study before January 24, 2020, was similar to the proportions reported by Li et al (1) (0/425, based on cases as of January 22, 2020) and Guan et al. (W.J. Guan et al., unpub. data, https://doi.org/1 0.1101/2020.02.06.20020974) (9/1,099 as of January 29, 2020). The possible reasons for the discrepancy after January 25 might be the low proportion of children exposed early in the outbreak; early detection for children who had had close contact with persons with diagnosed or suspected cases after strict control measures were conducted comprehensively; and difficult identification of the relatively milder clinical signs and symptoms in young patients than in infected adults (6), especially in the setting of limited resources in the early phase of the outbreak in Wuhan.

We explored the incubation periods for 58 casepatients with definite exposure and detailed investigation information. The estimated mean incubation periods were 6.1 (range 1-16) days among 33 casepatients who had had close contact with symptomatic confirmed case-patients and 6.0 (range 1-15) days among 25 case-patients who had traveled to Wuhan and stayed ≤1 day over the previous 3 weeks (Table 2; Appendix Table 1). Estimated incubation periods were consistent with those previously reported (1). We analyzed the characteristics of 74 clusters involving 183 cases (2-6 cases/cluster). Among 12 clusters of single intracluster transmission cases, 15 case-patients were infected within 5.5 days of the mean interval between illness onset of the infector and illness onset of the infectee. Among 56 clusters of single coexposure cases, the mean interval of symptom onset between the primary and second case-patient within a cluster was 3.1 days, and the mean interval of symptom onset between the primary and last case-patient within a cluster was 3.6 days (Appendix Table 2).

With continuous implementation of strict control measures, we observed a shortened span (median days

declining from 3 to 1; p<0.001) between illness onset and hospital visits for case-patients (Table 1). This finding may result from strict infection control management (e.g., early screening for suspected cases, monitoring for close-contact persons, and improved health consciousness of the general population).

To control the infection, confirmed case-patients should be separated and managed centrally; thus, the government has designated special hospitals to admit patients with suspected or confirmed cases. Nevertheless, as of February 5, to our knowledge, 1 case of a healthcare worker having been infected has been reported; an emergency nurse from a nondesignated hospital became ill on January 26, 2020, a total of 8 days after having been in close contact with a confirmed case-patient in the outpatient setting. We found that only 13%-15% of patients with confirmed cases went to the designated hospital first during the epidemic period. This finding means that a substantial number of case-patients visited ≥1 nondesignated hospital before they were admitted to the designated hospital, which increases the risk for nosocomial infection.

Conclusions

Essential for the control of this extremely contagious disease are close monitoring and timely reporting of the epidemic to the public as well as evaluation of the current control strategy. On the basis of this epidemiologic analysis, we found that COVID-19 has become endemic to Shenzhen, China. We suspect that community transmission and intrafamily transmission have potentially become the new transmission modes in the city. Also, nosocomial infection and transmission might pose a potential risk for COVID-19 control.

To control this outbreak in Shenzhen, maintaining basic and essential strategies is crucial. Early screening, diagnosis, isolation, and treatment are necessary to prevent further spread (7). Throughout the city, management of persons in close contact with persons with diagnosed and suspected cases, restriction of public activity, and use of personal protection measures should be continued. Strengthening effective and efficient measures, including but not limited to personal protection within families and communities with a high risk for exposure, will prevent and interrupt community and intrafamily transmission. To prevent nosocomial infection and transmission, a

designated hospital should be the first choice for persons who had close contact with confirmed casepatients or who themselves have clinical signs indicative of COVID-19.

Acknowledgment

We acknowledge the work and contribution of all health providers from Shenzhen Third People's Hospital and Shenzhen Center for Disease Control and Prevention in the detection, treatment, and control of the outbreak. We also acknowledge Zhiqiang Yao for his review of the manuscript.

About the Author

Dr. J. Liu is a clinical epidemiologist at The Institute of Hepatology, Shenzhen Third People's Hospital, Shenzhen, China. His research interests include the epidemiology, molecular characterization, and clinical outcomes of HIV/hepatitis B virus infection, and the control of emerging infectious diseases.


References

- Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. NEJM. 2020 Jan 31 [cited 2020 Feb 7]. https://www.nejm.org/doi/full/10.1056/ NEJMoa2001316
- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506 [cited 2020 Feb 7]. https://doi.org/10.1016/S0140-6736(20)30183-5
- Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–13 [cited 2020 Feb 7]. https://doi.org/10.1016/S0140-6736(20)30211-7
- Wang DW, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020 Feb 7 [cited 2020 Feb 16]. https://doi.org/10.1001/ jama.2020.1585
- Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395:514–23 [cited 2020 Feb 7]. https://doi.org/10.1016/S0140-6736(20)30154-9
- Chen ZM, Fu JF, Shu Q, Chen YH, Hua CZ, Li FB, et al. Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus. World J Pediatr. 2020 Feb 5 [cited 2020 Feb 7]. https://doi.org/10.1007/s12519-020-00345-5
- Wang FS, Zhang C. What to do next to control the 2019nCoV epidemic? Lancet. 2020;395:391–3 [cited 2020 Feb 7]. https://doi.org/10.1016/S0140-6736(20)30300-7

Address for correspondence: Zheng Zhang or Lei Liu, Shenzhen Third People's Hospital, Bulan Rd No. 29, Longgang District, Shenzhen, Guangdong 518112, China; email: zhangzheng1975@aliyun.com or liulei3322@aliyun.com

EID Podcast:The Mother of All Pandemics

Dr. David Morens, of the National Institute of Allergy and Infectious Diseases, discusses the 1918 influenza pandemic.



Visit our website to listen: https://tools.cdc.gov/medialibrary/ index.aspx#/media/id/393805

EMERGING INFECTIOUS DISEASES®

Community Transmission of Severe Acute Respiratory Syndrome Coronavirus 2, Shenzhen, China, 2020

Appendix

Appendix Table 1. The detailed case information for the analysis of the incubation period, stratified by exposure type

		Age		Incubation period	
Number	Sex	(Years)	Onset of illness	(Days)	Exposure
1	Female	53	2020/1/18	2	Travel to Wuhan and stay ≤1 day
2	Female	49	2020/1/18	7	Contact confirmed symptomatic case
3	Male	73	2020/1/20	1	Travel to Wuhan and stay ≤1 day
4	Male	66	2020/1/20	4	Travel to Wuhan and stay ≤1 day
5	Male	53	2020/1/20	8	Travel to Wuhan and stay ≤1 day
6	Male	38	2020/1/21	2	Travel to Wuhan and stay ≤1 day
7	Female	39	2020/1/22	1	Contact confirmed symptomatic case
8	Male	33	2020/1/22	6	Contact confirmed symptomatic case
9	Male	25	2020/1/22	2	Travel to Wuhan and stay ≤1 day
10	Male	31	2020/1/22	6	Contact confirmed symptomatic case
11	Female	78	2020/1/23	6	Contact confirmed symptomatic case
12	Female	33	2020/1/23	1	Contact confirmed symptomatic case
13	Female	32	2020/1/23	3	Travel to Wuhan and stay ≤1 day
14	Female	69	2020/1/24	5	Travel to Wuhan and stay ≤1 day
15	Male	61	2020/1/24	5	Contact confirmed symptomatic case
16	Female	59	2020/1/24	1	Contact confirmed symptomatic case
17	Male	38	2020/1/24	7	Travel to Wuhan and stay ≤1 day
18	Male	86	2020/1/25	2	Travel to Wuhan and stay ≤1 day
19	Female	62	2020/1/25	2	Contact confirmed symptomatic case
20	Female	32	2020/1/25	6	Contact confirmed symptomatic case
21	Male	41	2020/1/25	7	Travel to Wuhan and stay ≤1 day
22	Male	39	2020/1/25	2	Contact confirmed symptomatic case
23	Female	31	2020/1/25	3	Travel to Wuhan and stay ≤1 day
24	Male	47	2020/1/25	2	Contact confirmed symptomatic case
25	Male	48	2020/1/25	7	Travel to Wuhan and stay ≤1 day

		Age		Incubation period	
Number	Sex	(Years)	Onset of illness	(Days)	Exposure
26	Female	29	2020/1/26	5	Travel to Wuhan and stay ≤1 day
27	Female	33	2020/1/26	6	Travel to Wuhan and stay ≤1 day
28	Male	56	2020/1/26	1	Contact confirmed symptomatic cases
29	Male	41	2020/1/26	1	Contact confirmed symptomatic cases
30	Male	47	2020/1/26	7	Contact confirmed symptomatic cases
31	Male	65	2020/1/26	5	Contact confirmed symptomatic cases
32	Female	43	2020/1/26	5	Travel to Wuhan and stay ≤1 day
33	Female	25	2020/1/26	8	Contact confirmed symptomatic cases
34	Female	56	2020/1/26	4	Travel to Wuhan and stay ≤1 day
35	Female	35	2020/1/26	4	Contact confirmed symptomatic cases
36	Female	58	2020/1/27	4	Contact confirmed symptomatic cases
37	Female	38	2020/1/28	5	Contact confirmed symptomatic cases
38	Female	57	2020/1/28	10	Travel to Wuhan and stay ≤1 day
39	Female	50	2020/1/28	8	Contact confirmed symptomatic cases
40	Male	34	2020/1/28	10	Contact confirmed symptomatic cases
41	Male	40	2020/1/28	7	Travel to Wuhan and stay ≤1 day
42	Female	45	2020/1/29	5	Contact confirmed symptomatic cases
43	Female	40	2020/1/29	3	Contact confirmed symptomatic cases
44	Male	38	2020/1/29	5	Contact confirmed symptomatic cases
45	Male	45	2020/1/29	5	Travel to Wuhan and stay ≤1 day
46	Male	34	2020/1/29	10	Contact confirmed symptomatic cases
47	Female	7	2020/1/30	10	Travel to Wuhan and stay ≤1 day
48	Female	66	2020/1/30	10	Travel to Wuhan and stay ≤1 day
49	Female	65	2020/1/30	8	Contact confirmed symptomatic cases
50	Female	60	2020/1/31	9	Travel to Wuhan and stay ≤1 day
51	Female	58	2020/2/1	10	Travel to Wuhan and stay ≤1 day
52	Female	58	2020/2/2	5	Contact confirmed symptomatic cases
53	Male	31	2020/2/3	13	Contact confirmed symptomatic cases
54	Male	54	2020/2/3	15	Travel to Wuhan and stay ≤1 day
55	Male	2	2020/2/4	12	Contact confirmed symptomatic cases
56	Female	37	2020/2/4	14	Contact confirmed symptomatic cases
57	Female	37	2020/2/4	11	Contact confirmed symptomatic cases
58	Female	64	2020/2/5	16	Contact confirmed symptomatic cases

Appendix Table 2. The detailed case information for characteristic analysis of clusters

	Case		Illness onset	Interval of illness	Interval of illness		The	Interval of illness
	number		of primary	onset between the	onset between the	Co-exposure or	number of	onset between
Cluster	in	The relationship between primary case	cases in	primary case and	primary case and	intra-cluster	infectee in	infector and
number	cluster	and other cases	cluster	the second case	the last case	transmission	cluster	infectee
1	5	father-in-law, mother-in-law, son,	1-Jan	2	10	Both	1	4
		mother						
2	3	husband, one close contact	4-Jan	8	21	Both	1	10
3	2	husband, daughter-in-law	12-Jan	3	10	Both	1	12
4	2	wife	11-Jan	9	9	Co-exposure		
5	2	husband	19-Jan	1	1	Co-exposure		
6	4	wife, granddaughter, co-mother-in-	20-Jan	2	10	Co-exposure		
		law						
7	2	wife	16-Jan	0	0	Co-exposure		
8	2	wife	8-Jan	15	15	Co-exposure		
9	4	wife, son, daughter-in-law	20-Jan	2	4	Both	2	2, 4
10	2	wife	20-Jan	1	1	Co-exposure		
11	2	daughter	20-Jan	0	0	Co-exposure		
12	2	daughter	23-Jan	1	1	Co-exposure		
13	2	son	24-Jan	1	1	Intra-cluster	1	1
						transmission		
14	4	friends	20-Jan	3	6	Intra-cluster	3	3, 5, 6
						transmission		
15	5	wife, mother-in-law, daughter, wife,	23-Jan	1	4	Co-exposure		
		mother's sister						
16	4	sister, mother, daughter	22-Jan	1	7	Both	1	6
17	3	daughter, son-in-law	24-Jan	2	2	Intra-cluster	2	2, 2
						transmission		

	Case		Illness onset	Interval of illness	Interval of illness		The	Interval of illness
	number		of primary	onset between the	onset between the	Co-exposure or	number of	onset between
Cluster	in	The relationship between primary case	cases in	primary case and	primary case and	intra-cluster	infectee in	infector and
number	cluster	and other cases	cluster	the second case	the last case	transmission	cluster	infectee
18	5	wife, granddaughter1,	24-Jan	3	3	Both	1	0, 3
		granddaughter2, son						
19	2	husband	24-Jan	2	2	Co-exposure		
20	2	father	21-Jan	6	6	Co-exposure		
21	2	daughter	25-Jan	0	0	Co-exposure		
22	2	husband	23-Jan	6	6	Intra-cluster	1	6
						transmission		
23	4	wife, mother-in-law, father-in-law	19-Jan	6	7	Co-exposure		
24	2	husband	21-Jan	3	3	Co-exposure		
25	2	son	24-Jan	3	3	Co-exposure		
26	2	husband	23-Jan	2	2	Co-exposure		
27	2	son	18-Jan	6	6	Intra-cluster	1	6
						transmission		
28	2	husband	27-Jan	3	3	Co-exposure		
29	2	wife	24-Jan	5	5	Co-exposure		
30	2	wife	23-Jan	1	1	Co-exposure		
31	2	daughter	26-Jan	3	3	Co-exposure		
32	2	mother	26-Jan	1	1	Co-exposure		
33	2	husband	26-Jan	1	1	Co-exposure		
34	2	wife	27-Jan	1	1	Co-exposure		
35	2	wife	30-Jan	0	0	Co-exposure		
36	4	son, grandson, husband	24-Jan	4	6	Co-exposure		
37	2	wife	18-Jan	4	4	Co-exposure		

	Case		Illness onset	Interval of illness	Interval of illness		The	Interval of illness
	number		of primary	onset between the	onset between the	Co-exposure or	number of	onset between
Cluster	in	The relationship between primary case	cases in	primary case and	primary case and	intra-cluster	infectee in	infector and
number	cluster	and other cases	cluster	the second case	the last case	transmission	cluster	infectee
38	2	mother	28-Jan	3	3	Co-exposure		
39	4	wife, daughter, son	22-Jan	6	8	Co-exposure		
40	2	wife	23-Jan	1	1	Co-exposure		
41	2	wife	26-Jan	3	3	Co-exposure		
42	3	mother, father	25-Jan	3	6	Co-exposure		
43	2	daughter	26-Jan	6	6	Co-exposure		
44	2	grandson	28-Jan	4	4	Co-exposure		
45	2	daughter	24-Jan	7	7	Co-exposure		
46	2	husband	24-Jan	3	3	Co-exposure		
47	2	husband	18-Jan	5	5	Co-exposure		
48	2	husband	23-Jan	3	3	Co-exposure		
49	3	son, daughter-in-law	22-Jan	8	8	Co-exposure		
50	2	daughter	27-Jan	2	2	Co-exposure		
51	2	daughter-in-law	24-Jan	4	4	Intra-cluster	1	4
						transmission		
52	2	father	27-Jan	2	2	Co-exposure		
53	2	daughter	25-Jan	4	4	Co-exposure		
54	2	daughter-in-law	22-Jan	1	1	Co-exposure		
55	2	daughter	17-Jan	6	6	Intra-cluster	1	6
						transmission		
56	3	wife, daughter	1-Feb	1	1	Co-exposure		
57	2	wife	26-Jan	4	4	Intra-cluster	1	4
						transmission		
58	2	husband	25-Jan	1	1	Co-exposure		

	Case		Illness onset	Interval of illness	Interval of illness		The	Interval of illness
	number		of primary	onset between the	onset between the	Co-exposure or	number of	onset between
Cluster	in	The relationship between primary case	cases in	primary case and	primary case and	intra-cluster	infectee in	infector and
number	cluster	and other cases	cluster	the second case	the last case	transmission	cluster	infectee
59	3	girlfriend, father	3-Feb	1	1	Co-exposure		
60	2	wife	27-Jan	0	0	Co-exposure		
61	6	husband, daughter1, daughter2,	28-Jan	2	5	Co-exposure		
		father, mother						
62	2	son	24-Jan	10	10	Intra-cluster	1	10
						transmission		
63	2	husband	28-Jan	4	4	Co-exposure		
64	2	wife	27-Jan	0	0	Co-exposure		
65	2	son	27-Jan	9	9	Co-exposure		
66	2	son	26-Jan	0	0	Co-exposure		
67	2	daughter-in-law	19-Jan	16	16	Intra-cluster	1	16
						transmission		
68	2	wife	29-Jan	7	7	Intra-cluster	1	7
						transmission		
69	3	wife, daughter	27-Jan	7	9	Co-exposure		
70	2	wife	25-Jan	10	10	Co-exposure		
71	2	son	31-Jan	1	1	Co-exposure		
72	3	son, wife	3-Feb	2	2	Co-exposure		
73	2	sister	3-Feb	2	2	Co-exposure		
74	2	daughter	30-Jan	4	4	Intra-cluster	1	4
						transmission		



Appendix Figure 1. The location of Wuhan city and Shenzhen city, China.



Appendix Figure 2. Spatiotemporal dynamics of the first 365 confirmed cases of 2019-nCoV in Shenzhen, China. The geographic distribution of cases was presented based on the onset of illness as of January 10 (A), January 20 (B), January 31 (C), and February 5 (D).